Michael Duerr retweeted
How does GLP-1 produce a CV benefit?
Reduced body weight, glycaemia,
BP, postprandial lipaemia and inflammation.
Cardioprotective mechanisms are multiple and not perfectly understood, but undeniable, as shown by SELECT study.
nature.com/articles/s41569-0…
@sociedadSEEN @SociedadSeedo
Michael Duerr retweeted
Fresh from the press in @NatRevImmunol The 5 types of glomerulonephritis that connect pathogenesis with immunotherapy thanks to @PRomagnani @KitchingLab and Nelson Leung from Mayo nature.com/articles/s41577-0…
Michael Duerr retweeted
Four years ago, I spent the holidays intubated in an ICU with a sudden diagnosis of cardiogenic shock due to heart failure. Today, I thank my organ donor, Lucy, for giving me this #giftoflife ♻️ through heart transplantation. #thankyou #organdonation
Michael Duerr retweeted
The last outstanding #ESGCT2022 congress is over. It was an incredible success, and nothing could have been possible without your enthusiasm, dedication and passion for science.
It was a great week to learn and to connect at #ESGCT2022 #Edinburgh. Thanks the organizers @ESGCT to put an amazing program together. Safe travels for all attendees ✈️We are motivated and will facilitate #GCT for our patients💪💊 @BayerPharma
The Founder Award of #ESGCT2022 goes to Jude Samulski for his pioneering work on #AAV for #CGT. 🍾🎊Congrats Jude!!! Feel privileged and thankful to come to know him🙏@ask_bio @BayerPharma – at Edinburgh, Scotland
Outstanding Achievement Award 2022 #ESGCT2022 goes to Christof von Kalle #BIH @berlinnovation and to Manfred Schmidt posthumous to help leveraging the potential of #LMPCR by enabling studies of viral integration/viral vector tracking in #GCT. Very emotional ceremony! – at Edinburgh, Scotland
Presidential address given by Hildegard Büning. We are all very happy&thankful to be back at #ESGCT2022 to exchange newest data&network 🙏#GCT has a bright future with the potential to treat those pts who otherwise would never have a chance #Edinburgh #ASGCT #AAV #CRISP – at Edinburgh, Scotland
APOE4 gene is linked to higher risk for #Alzheimer Mike Kaplitt @WeillCornell presented first results on gene therapy with #AAV coding for APOE2 delivered via CSF to treat APOE4 #Alzheimer pts. Promising interim results #ESGCT2022 – at Edinburgh, Scotland
Learned a lot about new #gene #editing strategies on #huntington disease with #AAV Kami #Cas9 and with the help of human brain atlas to predict efficiency. Great educative talk-thanks to Nicole Deglon #ESGCT2022 – at Edinburgh, Scotland
Greg Gojanovic #AskBio showed with an empty #AAV capsid study a strong Ab & CD4 response despite absence of transgene. CD4/ICOS/PD1 was a identified phenotype who drives anti capsid response. Great talk&nice example how we can implement deep immune phenotyping in #CGT #ESGCT2022 – at Edinburgh, Scotland
Thanks @VivianGradinaru to show impressive data on gene delivery with #AAV across the blood brain barrier to possibly treat #parkinson #ataxia so far preclinical. I hope these results translate into clinic soon #caltech #ESGC2022 – at Edinburgh, Scotland
Treatment of devastating disease called #epidermolysis #bullosa with topical B-VEC, a HSV based redosable gene therapy to induce COL7 in skin showed impressive P3 trial results. Wounds healed with expressions of transfected collagen. #ESGCT2022 – at Edinburgh, Scotland
Absolutely amazing what #CRISP technology can deliver for pts with #sicklecell #thalassemia #ATTR #myopathy #hyperlipidemia. More indications will come! Great talk and thanks to @grunewaju #ESGCT2022
#Moderna works on #LNPs which can be delivered to different tissues. Also, one #LNP can be inhaled to target lung tissue. No safety concerns so far. #ESGCT2022
Great educative talk on oncolytic viruses and platforms towards new immuntherapies for cancer patients by @vincersurf #ESGCT2022
Traveling to #ESGCT2022 #Edinburgh. I’m so happy to learn more about the fascinating field of cell and gene therapies #CGT and to connect with colleagues and new people in the area. @ask_bio @BayerPharma #AAV esgctcongress.com
